Y-mAbs TherapeuticsYMAB
YMAB
About: Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Employees: 107
0
Funds holding %
of 7,407 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
525% more call options, than puts
Call options by funds: $50K | Put options by funds: $8K
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
64% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 11
26% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 31
6.45% more ownership
Funds ownership: 57.75% [Q3] → 64.2% (+6.45%) [Q4]
6% more funds holding
Funds holding: 105 [Q3] → 111 (+6) [Q4]
33% less capital invested
Capital invested by funds: $339M [Q3] → $225M (-$113M) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7
49%
upside
Avg. target
$12.25
161%
upside
High target
$18
284%
upside
4 analyst ratings
2 positive
50%
1 neutral
25%
1 negative
25%
HC Wainwright & Co. Robert Burns 16% 1-year accuracy 28 / 172 met price target | 156%upside $12 | Buy Maintained | 21 Mar 2025 |
B of A Securities Alec Stranahan 0% 1-year accuracy 0 / 8 met price target | 156%upside $12 | Neutral Maintained | 5 Mar 2025 |
Truist Securities Nicole Germino 54% 1-year accuracy 7 / 13 met price target | 284%upside $18 | Buy Maintained | 5 Mar 2025 |
Morgan Stanley Michael Ulz 20% 1-year accuracy 4 / 20 met price target | 49%upside $7 | Underweight Maintained | 5 Mar 2025 |
Financial journalist opinion
Positive
Seeking Alpha
6 days ago
Y-mAbs Therapeutics: A Yawn From The Market Means Opportunity
YMAB's naxitamab shows a 50% overall response rate in phase 2 trials for high-risk neuroblastoma, supporting its ongoing commercialization efforts. The SADA platform, targeting GD2 and CD38, is YMAB's main R&D focus, with crucial phase 1 readouts anticipated soon. Despite a net loss of $29.7 million, YMAB's $67.2 million cash position and steady naxitamab sales provide a cash runway into 2027.
Neutral
Seeking Alpha
1 month ago
Y-mAbs Therapeutics, Inc. (YMAB) Q4 2024 Earnings Call Transcript
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ET Company Participants Courtney Dugan - Head-IR Michael Rossi - President & CEO Doug Gentilcore - Senior VP & Head of DANYELZA Business Unit Natalie Tucker - Radiopharmaceutical Business Unit Head Peter Pfreundschuh - CFO Conference Call Participants Alec Stranahan - Bank of America Michael Wolf - Morgan Stanley Jeff Jones - Oppenheimer Nicole Germino - Truist Li Watsek - Cantor Fitzgerald William Maughan - Clear Street Justin Walsh - JonesTrading Robert Burns - H.C. Wainwright Kemp Dolliver - Brookline Capital Markets Operator Good morning and welcome to Y-mAbs Therapeutics Inc. Earnings Conference Call for the Fourth Quarter and Full Year 2024.
Negative
Zacks Investment Research
1 month ago
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Lags Revenue Estimates
Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.02 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 The Company established two business units in January 2025 aimed to accelerate the clinical development of its Radiopharmaceuticals Platform and optimize the commercial potential of DANYELZA Cash and cash equivalents of $67.2 million held as of December 31, 2024, reflects $11.4 million Total Annual Cash Investment in the full year 2024 Management announces Full Year 2025 guidance around Total Revenue, Operating Expenses, and Cash Investment and First Quarter 2025 guidance around Total Revenue The Company will host a conference call on Tuesday, March 4, 2025, at 8:00 a.m. ET NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today reported financial results for the fourth quarter and full year ended December 31, 2024.
Neutral
GlobeNewsWire
1 month ago
Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications
Naxitamab demonstrated clinically meaningful efficacy with manageable safety in patients with relapsed/refractory high-risk neuroblastoma and residual disease in bone/bone marrow Naxitamab demonstrated clinically meaningful efficacy with manageable safety in patients with relapsed/refractory high-risk neuroblastoma and residual disease in bone/bone marrow
Positive
Zacks Investment Research
1 month ago
Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
YmAbs Therapeutics (YMAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
1 month ago
Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report results for the fourth quarter and full year 2024 before the market open on Tuesday, March 4, 2025.
Neutral
GlobeNewsWire
2 months ago
Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference
NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Michael Rossi, President and Chief Executive Officer, will participate in a fireside chat at the Oppenheimer 35th Annual Life Sciences Conference on Tuesday, February 11, 2025 at 4:40 p.m. ET.
Negative
Zacks Investment Research
2 months ago
YmAbs Therapeutics (YMAB) Loses -25.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for YmAbs Therapeutics (YMAB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Negative
Zacks Investment Research
2 months ago
YmAbs Therapeutics (YMAB) Loses -26.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
YmAbs Therapeutics (YMAB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Charts implemented using Lightweight Charts™